2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonths
2019
Immune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancer
2010
Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method
Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method. Annals Of Surgical Oncology 2010, 18: 1775-1781. PMID: 21184188, DOI: 10.1245/s10434-010-1500-7.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerBladder cancerPolymerase chain reactionNonmuscle invasive bladder cancer patientsHOGG1 codon 326 genotypesProgression-free survival benefitInvasive bladder cancer patientsTumor tissueTissue genotypeHOGG1 codon 326Primary BC patientsCox regression analysisInvasive bladder cancerBladder cancer prognosisPrimary bladder cancerAggressive clinicopathological featuresBladder cancer patientsReal-time polymerase chain reactionSurvival benefitBC prognosisClinicopathological characteristicsClinicopathological featuresBC patientsPrognostic indicatorCancer patientsAnalysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping
Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorDNA GlycosylasesFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMusclesNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPeptide Nucleic AcidsPolymerase Chain ReactionPolymorphism, GeneticPrognosisProportional Hazards ModelsUrinary Bladder NeoplasmsConceptsMuscle-invasive bladder cancerReal-time PCR clampingInvasive bladder cancerBladder cancerHOGG1 genotypeHOGG1 codon 326 genotypesMultivariate Cox regression analysisHOGG1 codon 326Cancer-specific survivalCox regression analysisPrognostic genetic markersPCR clampingSpecific survivalSurvival benefitClinicopathologic characteristicsBC patientsPrognostic indicatorTumor gradePrognostic markerClinical dataProtective effectCancerPatientsDNA damage repair mechanismsCodon 326